公开(公告)号：US20240358647A1

公开(公告)日：2024-10-31

申请号：US18394246

申请日：2023-12-22

申请人： Oramed Ltd.

发明人： Avraham HERSHKO ,  Miriam KIDRON

IPC分类号： A61K9/48 ,  A61K9/19 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K38/56 ,  A61K47/42

CPC分类号： A61K9/4866 ,  A61K9/19 ,  A61K9/4858 ,  A61K9/4875 ,  A61K9/4891 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K38/56 ,  A61K47/42

摘要： Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same.

公开(公告)号：US20240336669A1

公开(公告)日：2024-10-10

申请号：US18266571

申请日：2021-12-10

申请人： IP21PO INNOVATIONS LIMTEED

发明人： Stephen Robert BLOOM

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61P3/04

CPC分类号： C07K14/605 ,  A61K38/26 ,  A61P3/04

摘要： The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

公开(公告)号：US20240325499A1

公开(公告)日：2024-10-03

申请号：US18600883

申请日：2024-03-11

申请人： SANOFI

发明人： Kathrin KÖRNER

IPC分类号： A61K38/26 ,  A61K38/00 ,  A61K38/18 ,  A61P3/10 ,  C07K14/50 ,  C07K14/605

CPC分类号： A61K38/26 ,  A61K38/1825 ,  A61P3/10 ,  C07K14/50 ,  C07K14/605 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30

摘要： The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

公开(公告)号：US20240325336A1

公开(公告)日：2024-10-03

申请号：US18258620

申请日：2021-12-21

申请人： NORTHSEA THERAPEUTICS B.V.

发明人： David Alan FRASER

IPC分类号： A61K31/202 ,  A61K31/519 ,  A61K31/575 ,  A61K38/26 ,  A61P1/16

CPC分类号： A61K31/202 ,  A61K31/519 ,  A61K31/575 ,  A61K38/26 ,  A61P1/16

摘要： The present disclosure provides a combination therapy for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH), wherein the combination therapy comprises an unsaturated fatty acid with an oxygen incorporated in the β-position and an α-substituent and at least one additional active agent chosen from a glucagon-like peptide 1 receptor agonist, an acetyl-CoA carboxylase inhibitor, and a farnesoid X receptor agonist.

公开(公告)号：US12102663B2

公开(公告)日：2024-10-01

申请号：US18172546

申请日：2023-02-22

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Tracey L. McLaughlin ,  Colleen M. Craig

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K38/22 ,  A61K38/26 ,  A61K45/06 ,  A61P3/08 ,  A61P3/10

CPC分类号： A61K38/2278 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/10 ,  A61K38/17 ,  A61K38/22 ,  A61K38/26 ,  A61K45/06 ,  A61P3/08

摘要： Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.

公开(公告)号：US12102633B2

公开(公告)日：2024-10-01

申请号：US18092723

申请日：2023-01-03

申请人： Quixgen, Inc.

发明人： Yusheng Xiong ,  Hong-Ping Guan ,  Wenjun Huang

IPC分类号： A61K31/4709 ,  A61K9/00 ,  A61K31/145 ,  A61K31/18 ,  A61K31/192 ,  A61K31/197 ,  A61K31/203 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4164 ,  A61K31/438 ,  A61K31/444 ,  A61K31/575 ,  A61K31/616 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/26 ,  A61K47/10 ,  A61K47/32 ,  A61K48/00 ,  A61P1/16 ,  A61P3/04 ,  A61P17/10 ,  C07D491/107 ,  C07D519/00

CPC分类号： A61K31/4709 ,  A61K9/0014 ,  A61K31/145 ,  A61K31/18 ,  A61K31/192 ,  A61K31/197 ,  A61K31/203 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4164 ,  A61K31/438 ,  A61K31/444 ,  A61K31/575 ,  A61K31/616 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/26 ,  A61K47/10 ,  A61K47/32 ,  A61K48/005 ,  A61P1/16 ,  A61P3/04 ,  A61P17/10 ,  C07D491/107 ,  C07D519/00

摘要： Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

公开(公告)号：US20240316154A1

公开(公告)日：2024-09-26

申请号：US18259500

申请日：2022-02-01

申请人： Eli Lilly and Company

发明人： Andrea Ferrante ,  Josef George Heuer ,  Stacey Lynn Lee ,  Petra Verdino

IPC分类号： A61K38/26 ,  A61K38/18 ,  A61K38/20 ,  A61K38/22 ,  A61K45/06 ,  C07K14/00

CPC分类号： A61K38/26 ,  A61K38/1883 ,  A61K38/2013 ,  A61K38/2221 ,  A61K45/06 ,  C07K14/00

摘要： The disclosure relates generally to biology and medicine, and more particularly it relates to compounds acting as half-life (t½)-extending moieties for use with therapeutics, especially for improving t½ of biological-based therapeutics (i.e., biotherapeutics or biologics). The disclosure further relates to fusions and conjugates that include one or more of the compounds acting as t½-extending moieties, as well as pharmaceutical compositions including the same and their use in treating various conditions, diseases or disorders.

公开(公告)号：US12084485B2

公开(公告)日：2024-09-10

申请号：US17553381

申请日：2021-12-16

申请人： Intarcia Therapeutics, Inc.

发明人： William Blackwell ,  Ved P. Srivastava ,  Mark Paulik

IPC分类号： A61K38/00 ,  A61K9/00 ,  A61K38/26 ,  A61P1/16 ,  A61P1/18 ,  A61P3/04 ,  A61P25/00 ,  C07K14/605

CPC分类号： C07K14/605 ,  A61K9/0004 ,  A61K38/26 ,  A61P1/16 ,  A61P3/04

摘要： This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

公开(公告)号：US20240293512A1

公开(公告)日：2024-09-05

申请号：US18565628

申请日：2022-06-30

申请人： HANMI PHARM. CO., LTD.

发明人： Jong Suk LEE ,  Yo Han KIM ,  Jung Kuk KIM ,  Sang Hyun LEE

IPC分类号： A61K38/26 ,  A61K31/351 ,  A61K31/382 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K47/68 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K38/26 ,  A61K31/351 ,  A61K31/382 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K47/6811 ,  A61K47/6889 ,  A61P3/04 ,  A61P3/10

摘要： A combination including a peptide having activities to all of glucagon, GLP-1, and GIP receptors or a conjugate thereof; and an SGLT-2 inhibitor is disclosed. Uses of the combination are also disclosed. The combination is suitable for use in treating metabolic syndrome, liver disease, lung disease, or respiratory infections in a subject in need thereof.

公开(公告)号：US20240293164A1

公开(公告)日：2024-09-05

申请号：US18593526

申请日：2024-03-01

申请人： Theromics, Inc.

发明人： William Keun Chan Park ,  Damian E. Dupuy

IPC分类号： A61B18/02 ,  A61B18/00 ,  A61K9/06 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/42 ,  A61K47/64 ,  A61K49/00

CPC分类号： A61B18/0218 ,  A61K9/06 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/42 ,  A61K47/643 ,  A61K49/0073 ,  A61B2018/00577

摘要： A method for cryoablation of a tissue of a patient includes positioning a cryoablation gel composition adjacent to a tissue of the patient, and cryoablating the tissue and cryoablation gel composition with a cryoprobe. The cryoablation gel composition includes a polymer carrier and a thermal accelerant bound to the polymer carrier. The cryoablation gel composition may include a therapeutic drug. Cryoablating the tissue and the cryoablation gel composition can achieve a lethal isotherm at temperatures between −30 and −50° C. in a shorter duration of time than when compared to cryoablating the tissue without the cryoablation gel composition. Cryoablating the tissue and cryoablation gel composition can achieve a larger treatment volume in the tissue than when compared to cryoablating the tissue without the cryoablation gel composition. Furthermore, cryoablating the tissue and cryoablation gel plus drug composition can release the drug to treat the cryoablated cells with the therapeutic drug.